samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we head towards the cooler weather, shorter days and bombardment of Autumn conferences, the annual BIO 2001 meeting in San Diego in June may seem like a long time ago. However, the memory of a marathon BIO with over 13,000 participants from all over the world, 700 exhibitors, 230 presenting companies and 15 conference tracks will probably stay with most of us for a long time to come. The sheer scale of the meeting and the buzz in the conference halls (and queues) reflected just how much the industry continues to grow and evolve in the post-2000 financing bonanza. Though times are now much tougher - with talk of recession on either side of the Atlantic, concern over the lack of leadership at the FDA, safety concerns, product withdrawals and manufacturing capacity problems (not forgetting the President Bush/stemcell/federal funding debate) - its not all doom and gloom for biotech. Many companies raised significant funds in the US and Europe last year and are now actively employing them in bringing products through development and negotiating higher value alliance deals with larger pharma partners. The pace of advance in science is also compelling and the blend of genomics, proteomics, informaticsand high throughput technologies is beginning to mature into new product development strategies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Helen Abbott
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement